Mimedx Group, Inc. MDXG
We take great care to ensure that the data presented and summarized in this overview for MIMEDX GROUP, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MDXG
View all-
Essex Woodlands Management, Inc. The Woodlands, TX28.2MShares$219 Million63.1% of portfolio
-
Black Rock Inc. New York, NY9.17MShares$71.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.92MShares$45.9 Million0.0% of portfolio
-
State Street Corp Boston, MA4.94MShares$38.3 Million0.0% of portfolio
-
Paradigm Capital Management Inc3.91MShares$30.3 Million1.46% of portfolio
-
Trigran Investments, Inc.3.26MShares$25.2 Million2.43% of portfolio
-
Geode Capital Management, LLC Boston, MA2.62MShares$20.3 Million0.0% of portfolio
-
Cannell Capital LLC Alta, WY2.43MShares$18.9 Million4.44% of portfolio
-
Morgan Stanley New York, NY1.93MShares$14.9 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.76MShares$13.6 Million0.02% of portfolio
Latest Institutional Activity in MDXG
Top Purchases
Top Sells
About MDXG
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.
Insider Transactions at MDXG
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 08
2024
|
William Frank Iv Hulse General Counsel and CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,896
-1.92%
|
$62,272
$7.2 P/Share
|
Apr 23
2024
|
William Frank Iv Hulse General Counsel and CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,896
-1.89%
|
$53,376
$6.51 P/Share
|
Apr 08
2024
|
William Frank Iv Hulse General Counsel and CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,896
-1.85%
|
$53,376
$6.9 P/Share
|
Mar 13
2024
|
William Frank Iv Hulse General Counsel and CAO |
SELL
Open market or private sale
|
Direct |
20,381
-4.07%
|
$142,667
$7.95 P/Share
|
Mar 04
2024
|
William Frank Iv Hulse General Counsel and CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
15,351
-2.98%
|
$122,808
$8.26 P/Share
|
Mar 01
2024
|
Rice Doug Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
58,478
+26.68%
|
-
|
Mar 01
2024
|
Ricci S Whitlow Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
58,478
+11.29%
|
-
|
Mar 01
2024
|
William Frank Iv Hulse General Counsel and CAO |
BUY
Grant, award, or other acquisition
|
Direct |
59,127
+10.29%
|
-
|
Feb 20
2024
|
Ricci S Whitlow Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
15,271
-3.67%
|
$122,168
$8.01 P/Share
|
Feb 16
2024
|
Ricci S Whitlow Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
15,493
-3.59%
|
$123,944
$8.07 P/Share
|
Feb 15
2024
|
Ricci S Whitlow Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
15,198
-3.4%
|
$121,584
$8.06 P/Share
|
Feb 14
2024
|
Ricci S Whitlow Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
15,845
-3.42%
|
$126,760
$8.03 P/Share
|
Dec 22
2023
|
Falcon Fund 2 Holding Company, L.P. |
BUY
Conversion of derivative security
|
Direct |
28,195,249
+50.0%
|
-
|
Nov 21
2023
|
Rice Doug Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+4.66%
|
$35,000
$7.16 P/Share
|
Jul 05
2023
|
Rice Doug Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
97,200
+50.0%
|
-
|
Jun 23
2023
|
Joseph H Capper Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
42,025
+29.59%
|
$252,150
$6.5 P/Share
|
Jun 22
2023
|
Joseph H Capper Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
57,975
+50.0%
|
$347,850
$6.33 P/Share
|
Jun 13
2023
|
M Kathleen Behrens Director |
BUY
Grant, award, or other acquisition
|
Direct |
35,354
+18.01%
|
$141,416
$4.95 P/Share
|
Jun 13
2023
|
James L Bierman Director |
BUY
Grant, award, or other acquisition
|
Direct |
35,354
+18.01%
|
$141,416
$4.95 P/Share
|
Jun 13
2023
|
Phyllis Gardner Director |
BUY
Grant, award, or other acquisition
|
Direct |
35,354
+23.2%
|
$141,416
$4.95 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 521K shares |
---|---|
Open market or private purchase | 105K shares |
Conversion of derivative security | 28.2M shares |
Open market or private sale | 82.2K shares |
---|---|
Payment of exercise price or tax liability | 42K shares |